Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Increases By 87.5%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 100,300 shares, a growth of 87.5% from the August 31st total of 53,500 shares. Based on an average daily volume of 134,500 shares, the days-to-cover ratio is currently 0.7 days. Based on an average daily volume of 134,500 shares, the days-to-cover ratio is currently 0.7 days.

Astellas Pharma Trading Down 1.1%

Shares of ALPMY opened at $11.02 on Monday. Astellas Pharma has a twelve month low of $8.37 and a twelve month high of $12.45. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.17 and a quick ratio of 0.89. The firm has a fifty day simple moving average of $11.09 and a two-hundred day simple moving average of $10.12.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Wednesday, July 30th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.26. Astellas Pharma had a net margin of 4.34% and a return on equity of 19.67%. The company had revenue of $3.41 billion during the quarter, compared to analyst estimates of $3.20 billion. As a group, equities analysts predict that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALPMY has been the subject of several research reports. Zacks Research raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 9th. Sanford C. Bernstein cut shares of Astellas Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Astellas Pharma currently has an average rating of “Buy”.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.